Skip to main content
. Author manuscript; available in PMC: 2010 Nov 8.
Published in final edited form as: Cancer Gene Ther. 2007 Dec 14;15(2):115–125. doi: 10.1038/sj.cgt.7701110

Figure 7. Actuarial survival of C57BL/6 mice after intraperitoneal administration of vvDD-CD and subsequent treatment with 5-FC.

Figure 7

MOSEC tumor-bearing mice were treated with HBSS or vvDD-CD at 1.0 × 109 pfu per mouse on day 30 after tumor cell inoculation. On day 4 following vvDD-CD administration, animals were treated with 5-FC or vehicle as described in Materials and Methods. The groups of mice are, [1], control; [2], HBSS + 5-FC; [3]: vvDD-CD + HBSS; and [4], vvDD-CD + 5-FC. Survival data is displayed on a Kaplan-Meier plot, and differences in survival were determined by log rank test. The p values between different groups are, [1] vs. [2], p< 0.224; [1] vs. [3], p < 8.0 × 10e-6; [1] vs. [4], p < 8.0 × 10e-6; [2] vs. [3], p < 1.9 × 10e-5; [2] vs. [4], p < 1.9 × 10e-5; and [3] vs. [4], p < 0.0075.